- •Achromobacter species are emerging pathogens isolated from respiratory samples of patients with cystic fibrosis causing growing concerns in the CF community.
- •European CF society patient registry data was analysed for association between Achromobacter infection and demographic/clinical characteristics and outcomes.
- •Patient infected with Achromobacter had similar pulmonary function and BMI to patients infected with P. aeruginosa at all age groups.
- •Being infected with both bacteria was associated with significantly lower pulmonary function and BMI at all age groups.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment.J Cyst Fibros. 2011; 10 (Dec): 466-469
- Genetic adaptation of Achromobacter sp. during persistence in the lungs of cystic fibrosis patients.PLoS ONE. 2015; 10e0136790
- Identification and distribution of Achromobacter species in cystic fibrosis.J Cyst Fibros. 2013; 12 (May): 298-301
- Alcaligenes infection in cystic fibrosis.Pediatr Pulmonol. 2002; 34 (Aug): 101-104
- Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.J Cyst Fibros. 2007; 6 (Jan): 75-78
- Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients.APMIS. 2008; 116 (Sep): 837-841
- Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients.Eur J Clin Microbiol Infect Dis. 2011; 30 (Aug): 973-980
- Clinical outcomes associated with Achromobacter.Ann Am Thorac Soc. 2017; 14: 1412-1418
- Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients.Eur J Clin Microbiol Infect Dis. 2009; 28: 191-195
- Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.Chest. 2009; 136: 1554-1560
- Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients.APMIS. 2008; 116: 837-841
- Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.J Clin Microbiol. 2013; 51: 1927-1930
- Microbiology of sputum from patients at cystic fibrosis centers in the United States.Clin Infect Dis. 1998; 27: 158-163
- Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients.J Clin Microbiol. 2011; 49: 3649-3651
- Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study.J Cyst Fibros. 2006; 5: 245-251
- Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.J Cyst Fibros. 2007; 6: 75-78
- Prevalence and outcomes of Achromobacter species infections in adults with cystic fibrosis: a north american cohort study.J Clin Microbiol. 2017; 55 (Jul): 2074-2085https://doi.org/10.1128/JCM.02556-16
Zolin, A., Orenti, A., Naehrlich, L., Jung, A., van Rens, J. et al. (2020) ECFSPR Annual Report 2018.
- Genotype -phenotype correlations in cystic fibrosis.Pediatr Pulmonol. 1996; 22: 387-395
- Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.J Cyst Fibros. 2003; 2: 29-34
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations.Eur Respir J. 2012; 40: 1324-1343
- 2000 CDC growth charts for the United States: methods and development. National Centre for Health Statistics.Vital Health Stat. 2002; 11: 1-190
- Longitudinal data analysis using generalized linear models.Biometrika. 1986; 78: 13-22
- Impact of sustained eradication of new pseudomonas aeruginosa infection on long-term outcomes in cystic fibrosis.Clin Infect Dis. 2015; 61 (Sep 1): 707-715
- Decade-long bacterial community dynamics in cystic fibrosis airways.Proc Natl Acad Sci U S A. 2012; 109 (Apr 10Epub 2012 Mar 26. PMID: 22451929; PMCID: PMC3326496): 5809-5814https://doi.org/10.1073/pnas.1120577109
- Rapid detection of emerging pathogens and loss of microbial diversity associated with severe lung disease in cystic fibrosis.J Clin Microbiol. 2015; 53 (JulEpub 2015 Apr 15. PMID: 25878338; PMCID: PMC4473198): 2022-2029https://doi.org/10.1128/JCM.00432-15
- Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis.Paediatr Respir Rev. 2016; (Aug;20 SupplEpub 2016 Jun 15. PMID: 27374622): 27-29https://doi.org/10.1016/j.prrv.2016.06.011